BETA-BLOCKER USE IS ASSOCIATED WITH INCREASED ALL-CAUSE MORTALITY IN LUNG CANCER PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS

Whether beta blockers (BB) affect clinical outcomes in cancer patients receiving immunotherapy is unknown. We retrospectively reviewed our database for patients who received immune checkpoint inhibitors (CPI). Between 03/2010 and 07/2019, 3,326 patients received CPI. Use of BB prior to CPI was